The main concern is about the lack of predictivity of animal models.95% of failures between the preclinical and clinical stages of drug development!Another important research area is the the factors predicting the response to drugs at the individual level (personalized medicine). The equivalent in drug industries is the codevelopment of molecular targeted drugs and companion diagnostics.The area where these trends are the most important is oncology but others are coming ( hepatology,metabolic diseases)
Please answer anyone, how correct is the intravenous administration of recombinant protein in the rat tail vein. I have a suspicion that my protein aggregates or destroyed by this method of administration.
I suspect that there is shortage of new classical drugs in the pipeline, esp. in infectious diseases. So, as mentioned before pharmacogenetics and targeted therapies are now the main stream.
The main concern is about the lack of predictivity of animal models.95% of failures between the preclinical and clinical stages of drug development!Another important research area is the the factors predicting the response to drugs at the individual level (personalized medicine). The equivalent in drug industries is the codevelopment of molecular targeted drugs and companion diagnostics.The area where these trends are the most important is oncology but others are coming ( hepatology,metabolic diseases)
Fortunately for those of us working in heart, vessels and microvessels the accurate assessment of Pr Perret on the poor predictability of animal models, is thankfully not (and never has been) applicable to cardiovascular sciences.